PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|June 2, 2016
- Pharmaceutical Technology-06-02-2016
- Volume 40
- Issue 6
Dropper Eliminates Need for Isolation and Insertion
The MD-Dropper Cap from HealthStar is a new dropper bottle technology for blow-fill-seal (BFS) technology.
The MD-Dropper Cap from HealthStar is a new dropper bottle technology for blow-fill-seal (BFS) technology. The design produces metered-dose eye drops with standard BFS technology, without the added step of isolation/insertion technology. The containers are molded using standard BFS manufacturing machines and procedures. Cycle times are maintained at normal BFS output levels, typically around 12 seconds. The pre-assembled and sterilized containers are snapped onto the BFS containers post manufacturing in a cleanroom environment. The contents of the bottle are never in contact with the MD-Dropper Cap until activated by the patient.
Articles in this issue
over 10 years ago
Modern Manufacturing Comes of Ageover 10 years ago
Examining Blow-Fill-Seal Technology for Aseptic Processesover 10 years ago
Demonstrating a State of Controlover 10 years ago
PAT: “Gateway Drug” to the 21st Century for the Pharma Industryover 10 years ago
Watch Out for the Hangoverover 10 years ago
Deciding When To Use Modular Constructionover 10 years ago
Integrating Single-Use Systems in Pharma Manufacturingover 10 years ago
Steps Closer to the Adoption of Continuous Processingover 10 years ago
Industry Moves Closer to Continuous ManufacturingRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.